ESMO 2017 | Exciting results from the ALEX trial

Silvia Novello, MD, PhD, from the San Luigi Hospital, Orbassano, Italy, discusses her presentation at the European Society for Medical Oncology (ESMO) 2017 in Madrid, Spain. The ALEX trial (NCT02075840) is a Phase III randomised trial comparing alectinib and crizotinib in ALK positive non-small cell lung cancer patients. The primary endpoint of the trial was met, showing an advantage in terms of progression free survival. There was also interesting data regarding patients with brain metastases.